Results of the Cancer Screening Feasibility Study in China: a Multicentered Randomized Controlled Trial of Lung and Colorectal Cancer Screening

Overview

Journal J Natl Cancer Cent

Specialty Oncology

Date 2024 Jul 22

PMID 39036801

Authors

Jiang Li

Ping Hu

Jufang Shi

Yaguang Fan

Jiansong Ren

Hongda Chen

Ni Li

Xianzhen Liao

Yuqin Liu

Lingbin Du

Ning Wu

Wei Tang

Yueming Zhang

Shuangmei Zou

Paul Pinsky

Philip Prorok

Richard Fagerstrom

Martina Taylor

Barnett Kramer

Min Dai

Jie He

Affiliations

Soon will be listed here.

Abstract

Background: To provide an understanding of important aspects of the participant recruitment and data collection, become aware of any potential problems, and obtain necessary information in order to design a large-scale randomized controlled trial (RCT) for lung cancer and colorectal cancer (CRC) screening in China.

Methods: This feasibility study was a multicentered, open-label, pilot randomized trial. A total of 2696 participants who were at high risk of lung cancer were recruited from three screening centers and randomly allocated to arm 1 ( = 894), annual low-dose computed tomography (LDCT) plus a baseline colonoscopy; arm 2 ( = 902), biennial LDCT plus annual fecal immunochemical test (FIT) with OC-Sensor (OC-FIT); and arm 3 ( = 900), annual Insure-FIT plus Septin 9 blood test. Information on randomization, compliance, positivity rate, cancer case detection, and contamination with screening for lung cancer and CRC were collected.

Results: Participant characteristics were similar across study arms. The compliance rate of annual LDCT screening in arm 1 was 86.4% (95% CI: 83.9%, 88.5%) at baseline (T0), and 69.0% (95% CI: 65.8%, 72.0%) and 70.7% (95% CI: 67.6%, 73.7%) at the following two rounds (T1 and T2). The compliance rates of biennial LDCT screening in arm 2 were similar to those in arm 1 in the corresponding rounds. The compliance rate was 55.5% (95% CI: 52.2%, 58.8%) for colonoscopy in arm 1, while the compliance rates of OC-FIT, Insure-FIT, and the Septin 9 test in arms 2 and 3 were all approximately 90% at T0, decreasing to 65%-80% at T1 and T2. The positivity rate, cancer case detection rate, and contamination rate of screening for lung cancer and CRC were also reported.

Conclusion: In this pilot study, the feasibility of an RCT in China of lung cancer and CRC screening was demonstrated.

Citing Articles

National lung cancer screening program feasibility study in Estonia.

Kallavus K, Laisaar K, Ratsep A, Kiudma T, Takker U, Poola A Interdiscip Cardiovasc Thorac Surg. 2023; 36(6).

PMID: 36807427 PMC: 10279650. DOI: 10.1093/icvts/ivad041.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Kapidzic A, Grobbee E, Hol L, van Roon A, van Vuuren A, Spijker W . Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol. 2014; 109(8):1257-64. DOI: 10.1038/ajg.2014.168. View

Liu S, Chen Q, Guo L, Cao X, Sun X, Chen W . Incidence and mortality of lung cancer in China, 20082012. Chin J Cancer Res. 2019; 30(6):580-587. PMC: 6328502. DOI: 10.21147/j.issn.1000-9604.2018.06.02. View

Patz Jr E, Greco E, Gatsonis C, Pinsky P, Kramer B, Aberle D . Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. 2016; 17(5):590-9. PMC: 5094059. DOI: 10.1016/S1470-2045(15)00621-X. View

Sverzellati N, Silva M, Calareso G, Galeone C, Marchiano A, Sestini S . Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen. Eur Radiol. 2016; 26(11):3821-3829. DOI: 10.1007/s00330-016-4228-3. View

Passamonti B, Malaspina M, Fraser C, Tintori B, Carlani A, DAngelo V . A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer. Gut. 2016; 67(3):485-496. DOI: 10.1136/gutjnl-2016-312716. View

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

Osborne J, Wilson C, Duncan A, Cole S, Flight I, Turnbull D . Patterns of participation over four rounds of annual fecal immunochemical test-based screening for colorectal cancer: what predicts rescreening?. BMC Public Health. 2017; 18(1):81. PMC: 5540393. DOI: 10.1186/s12889-017-4634-8. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

10.

Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S . Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2014; 64(5):784-90. DOI: 10.1136/gutjnl-2014-307508. View

11.

Zhou Q, Fan Y, Wu N, Huang Y, Wang Y, Li L . Demonstration program of population-based lung cancer screening in China: Rationale and study design. Thorac Cancer. 2016; 5(3):197-203. PMC: 4704303. DOI: 10.1111/1759-7714.12078. View

12.

Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T . Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014; 14:183. PMC: 4287474. DOI: 10.1186/1471-230X-14-183. View

13.

van der Aalst C, Ten Haaf K, de Koning H . Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016; 4(9):749-761. DOI: 10.1016/S2213-2600(16)30200-4. View

14.

Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P . Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 2004; 47(1):9-15. DOI: 10.1016/j.lungcan.2004.06.007. View

15.

Swensen S, Jett J, Sloan J, Midthun D, Hartman T, Sykes A . Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002; 165(4):508-13. DOI: 10.1164/ajrccm.165.4.2107006. View

16.

Becker N, Motsch E, Trotter A, Heussel C, Dienemann H, Schnabel P . Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer. 2019; 146(6):1503-1513. DOI: 10.1002/ijc.32486. View

17.

Helsingen L, Vandvik P, Jodal H, Agoritsas T, Lytvyn L, Anderson J . Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019; 367:l5515. DOI: 10.1136/bmj.l5515. View

18.

Henschke C, McCauley D, Yankelevitz D, Naidich D, McGuinness G, Miettinen O . Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999; 354(9173):99-105. DOI: 10.1016/S0140-6736(99)06093-6. View

19.

Paci E, Puliti D, Pegna A, Carrozzi L, Picozzi G, Falaschi F . Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. 2017; 72(9):825-831. DOI: 10.1136/thoraxjnl-2016-209825. View

20.

Rex D, Boland C, Dominitz J, Giardiello F, Johnson D, Kaltenbach T . Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017; 153(1):307-323. DOI: 10.1053/j.gastro.2017.05.013. View